Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in Ankylosing Spondylitis
NCT02047110Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2014
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of risankizumab in ankylosing spondylitis (AS), sponsored by AbbVie Inc.. Started Jan 2014; status: completed.
02
Drugs
risankizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02047110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047110.